STOCK TITAN
  1. Home
  2. Sec-filings
  3. SMTI
  4. [Form 4] Sanara MedTech Inc. Insider Trading Activity

Sanara MedTech (SMTI) director Ronald Nixon receives 4,154 restricted shares grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nixon Ronald T reported acquisition or exercise transactions in this Form 4 filing.

Sanara MedTech Inc. director and 10% owner Ronald T. Nixon received a grant of 4,154 shares of restricted common stock as equity compensation. The award was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan at no cash cost to him.

The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, if he continues providing certain services to the company through that date. Following this grant, he holds 68,196 shares of common stock directly.

In addition, separate from his direct holdings, 963,856 shares are owned of record by CGI Cellerate RX, LLC and 2,452,731 shares are owned of record by FA Sanara, LLC. These entities may share voting and dispositive control with Mr. Nixon and related entities, who disclaim beneficial ownership of those shares except to the extent of their pecuniary interests.

Positive

  • None.

Negative

  • None.
Insider Nixon Ronald T
Role null
Type Security Shares Price Value
Grant/Award Common Stock 4,154 $0.00 --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 68,196 shares (Direct, null); Common Stock — 2,452,731 shares (Indirect, See Footnote)
Footnotes (1)
  1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date. Represents shares of the Issuer's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein. Represents shares of the Issuer's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.
Restricted stock grant 4,154 shares Grant of restricted common stock to Ronald T. Nixon
Direct holdings after grant 68,196 shares Common stock directly held by Ronald T. Nixon after grant
Indirect holdings via CGI Cellerate RX, LLC 963,856 shares Common stock owned of record by CGI Cellerate RX, LLC
Indirect holdings via FA Sanara, LLC 2,452,731 shares Common stock owned of record by FA Sanara, LLC
Vesting date outer limit June 4, 2027 Latest vesting date for restricted stock if service condition met
restricted stock financial
"Represents shares of restricted stock granted by Sanara MedTech Inc."
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
2024 Omnibus Long-Term Incentive Plan financial
"granted by Sanara MedTech Inc. pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan"
voting and dispositive control financial
"may be deemed to share voting and dispositive control over the common stock"
beneficial ownership financial
"disclaim beneficial ownership of any common stock held or beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nixon Ronald T
(Last)(First)(Middle)
1200 SUMMIT AVE
SUITE 414
(Street)
FORT WORTH TEXAS 76102
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Sanara MedTech Inc. [ SMTI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026A4,154(1)A$068,196D
Common Stock2,452,731ISee Footnote(2)
Common Stock963,856ISee Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of restricted stock granted by Sanara MedTech Inc. (the "Issuer") to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027, provided that the reporting person is providing certain services to the Issuer through such date.
2. Represents shares of the Issuer's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.
3. Represents shares of the Issuer's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.
/s/ Ronald T. Nixon06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ronald T. Nixon report at Sanara MedTech (SMTI)?

Ronald T. Nixon reported receiving 4,154 shares of restricted common stock as an equity grant. The award was issued at no cash cost to him and is part of his compensation from Sanara MedTech Inc. under a long-term incentive plan.

When do Ronald T. Nixon’s new restricted SMTI shares vest?

The 4,154 restricted shares vest on the earlier of the 2027 annual shareholder meeting or June 4, 2027. Vesting requires that Mr. Nixon continue providing certain services to Sanara MedTech Inc. through the applicable vesting date.

How many Sanara MedTech (SMTI) shares does Ronald T. Nixon now hold directly?

After the restricted stock grant, Ronald T. Nixon directly holds 68,196 shares of Sanara MedTech common stock. This total reflects his direct ownership only and is separate from additional shares held indirectly through affiliated entities.

What indirect Sanara MedTech (SMTI) holdings are associated with Ronald T. Nixon?

Affiliated entities hold 963,856 shares through CGI Cellerate RX, LLC and 2,452,731 shares through FA Sanara, LLC. Mr. Nixon and related entities may share voting and dispositive control but disclaim beneficial ownership except for their pecuniary interests.

Was Ronald T. Nixon’s recent SMTI Form 4 a market purchase or sale?

The Form 4 reflects an equity grant of 4,154 restricted shares, not a market trade. The grant is classified as a compensation-related acquisition and carries a transaction code A, indicating a grant, award, or other acquisition.